Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock closed at a record high.
Published . Updated .
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
Directly affected
- No company is named in this report.
Indirectly affected
- No related companies are mapped for this report yet.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
Source: MarketWatch
This story
12 out of 100
“Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock closed at a record high.” scores 12 out of 100. The score uses 1 sources.